why choose us

First received: October 10, 2023

Clinical Trial: A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Allergic Conjunctivitis

Study Type: INTERVENTIONAL


Official Title: A Single Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Con

Brief Summary: In this prospective Phase 2, single-center, randomized, double-masked, placebo-controlled study, approximately 70 subjects with allergic conjunctivitis will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.

Read more